MP-470 granted orphan drug designation

被引：0

|

作者：

不详

机构：

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2008年 / 8卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：1373 / 1373

页数：1

相关论文

共 50 条

[41] Hemophilia drug OBI-1 receives orphan drug designation in Europe
Reeve, Emily
[J]. EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (06) : 662 - 662
[42] NEGOTIATION OUTCOMES IN ITALY: WHAT'S THE IMPACT OF ORPHAN DRUG DESIGNATION?
Enrici, A.
Lidonnici, D.
Lanati, E.
[J]. VALUE IN HEALTH, 2019, 22 : S716 - S717
[43] HGS receives orphan drug designation for antibody-stimulating protein
不详
[J]. BIOTECHNOLOGY LAW REPORT, 2001, 20 (04) : 554 - 554
[44] Orphan drug designation and development in Japan: 25 years of experience and assessment
Sakushima, Ken
Takeda, Hiroshi
Aoi, Yoko
[J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (12) : 893 - 894
[45] FDA Grants Orphan Drug Designation for 68Ga-DOTATOC
不详
[J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01)
[46] Orphan drug designation and development in Japan: 25 years of experience and assessment
Ken Sakushima
Hiroshi Takeda
Yoko Aoi
[J]. Nature Reviews Drug Discovery, 2021, 20 : 893 - 894
[47] A PHASE 1B DOSE ESCALATION STUDY OF MP-470 ADMINISTERED CONCURRENTLY WITH STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH NSCLC AND SCLC
Mita, M.
Tolcher, A.
Gordon, M.
Rosen, L.
Fine, G. D.
Choy, G. S.
Berk, G. I.
Mita, A.
[J]. LUNG CANCER, 2009, 64 : S57 - S57
[48] Pharmaceuticals -: Anagrelide granted orphan status
不详
[J]. CHEMISTRY & INDUSTRY, 2001, (02) : 34 - 34
[49] ORPHAN DRUG DESIGNATION: NO IMPACT ON P&R PROCESS TIMING IN ITALY
Enrici, A.
Lidonnici, D.
Isernia, M.
Lanati, E.
[J]. VALUE IN HEALTH, 2019, 22 : S716 - S716
[50] Worldwide collaboration for orphan drug designation (vol 15 , pg 440, 2016)
Mariz, Segundo
Reese, James H.
Westermark, Kerstin
Greene, Lesley
Goto, Takahiro
Hoshino, Tatsuro
Llinares-Garcia, Jordi
Sepodes, Bruno
[J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (08) : 589 - 589

← 1 2 3 4 5 →